|Follow us :|
Luai Al Bakour
El Temamy Pharmacy
Akoni Hijyen Teknolojileri Sanayi ve Dış Ticaret LTD. ŞTİ
Britton Chance Center for Biomedical Photonics
Arabian Trade Center - ATC
Medical Facility (32206):
Legality International. (Pvt.) Ltd.
MainYou must sign in to use this servcie
Feedback - Please use the form below to send your query or comment
You must sign in to use this servcie
Inflammatory diseases of the joints. Osteoarthritis. Pain following surgery. Sciatica.
It is contra-indicated in the following groups of patients those allergic to lornoxicam, or any of its excipients
General : Headache, dizziness, somnolence, changes in appetite, increased sweating, loss of weight, oedema, allergic reactions, debility, weight increase. Central nervous system (CNS): Depression, insomnia. Eyes : Conjunctivitis, vision disorders. Gastro-intestinal: Abdominal pain, diarrhoea, dyspepsia, nausea, vomiting, flatulence, dysphagia, constipation, gastritis, dry mouth, stomatitis, gastro-esophageal reflux, peptic ulceration with or without bleeding, esophagitis, haemorrhoidal or rectal bleeding. Haematological : Anemia, ecchymosis, prolonged bleeding time, thrombocytopenia Liver: Increased transaminases. Musculo-skeletal: Cramps in leg, myalgia. Neurological : Migraine, paraesthesia, taste perversion, tinnitus and tremor. Respiratory : Dyspnoea, symptoms of irritation in upper respiratory tract. Skin: Allergic skin reactions such as dermatitis, flushing and pruritis, loss of hair. Urogenital : Micturition disorders. Vascular : Palpitations, tachycardia, changes in blood pressure.
Anticoagulants. Sulphonylureas. Diuretics/ACE inhibitors/Digoxin. Lithium. Methotrexate/Ciclosporin. Cimetidine.
In patients with the following disorders, Lornoxicam should only be administered after careful risk-benefit assessment (see also Special precautions): Gastro-intestinal ulceration and bleeding in medical history; previous cerebrovascular haemorrhage; SLE; ulcerative colitis; Crohnas disease; porphyria; haematopoietic disorders; patients with reduced cardiac function. When treating patients with mild to moderate cardiac failure, attention must be paid to the risk of fluid retention and decreased renal function. Liver diseases (e.g. liver cirrhosis).
SOLUTION FOR INJECTION
Dosage and AdministrationYou must sign in to use this servcie
Technical DescriptionYou must sign in to use this servcie
Dr. Talal Sabouni
Dr. Hani Najjar
Dr . Dirar Abboud
Yaser Habrawi , F.R.C.S.Ed
Dr. Samer Al-Jneidy
Dr. Faisal Dibsi
Samir Moussa M.D.
Dr. Tahsin Martini